Beyond this, germline BRCA1 mutations are associated with an almost 4-fold increased risk of PC, BRCA2 nearly 8.6-fold higher risk than the general population, as well as predisposition to PC onset at an earlier age (less than 55 years) and higher grade, locally advanced or advanced disease, or higher incidence of prostate tumor recurrence after primary treatment. The gene discussed is BRCA2; the disease is pachyonychia congenita.